Our projects:
- The role of DNASE1L3 in the regulation of tumor-derived DNA immunogenicity.
- Function of DNASE1L3 in the pathogenesis of systemic sclerosis.The role of DNASE1L3 in the development of metabolic syndrome and type II diabetes induced by obesity
- Function of DNASE1L3 in the pathogenesis of systemic sclerosis.
Beyond the regulation of self-DNA sensing we have developed projects to investigate the mechanisms that regulate anti-tumor immune responses.
- The role of follicular T helper cells in the pathogenesis of Chronic Lymphocytic Leukemia (CLL).
Dr. Dorothée Duluc leads this project, in collaboration with Dr. Edouard Forcade (clinician at Haut-Lévêque hospital). The goal is to understand the role of follicular helper cells in CLL pathogenesis and particularly their implication in CLL tumor growth.
- The role gut-derived T cells in anti-tumor immunity that either occur spontaneously or in response to immunotherapies. This project is developed in collaboration with Dr. Nathalie Schmitt team at Immunoconcept. The goal is to understand how gut microbiota influence anti-tumor immunity induced by immunotherapies. We are hypothesizing that T cells primed in the gut may be recruited to the tumors site and play a crucial role in the induction of anti-tumor immune response.
- The impact of aging on spontaneous and immunotherapy induced anti-tumor immune responses.
This project is developed in collaboration with Dr. David Santamaria and the SIRIC BRIO. The goal is to understand how aging may influence the development of tumors and particularly how aging impact cancer surveillance by the immune system and the efficacy of immunotherapies.
